Online Supplemental Material
to
Aspirin Treatment and Outcomes after PCI –
Results of the Intracoronary Stenting and Antithrombotic Regimen –
ASpirin and Platelet Inhibition (ISAR-ASPI) Registry
Authors: Katharina Mayer,* Isabell Bernlochner,† Siegmund Braun,* Stefanie Schulz,*
Martin Orban,‡ Tanja Morath,* Lisena Cala,* Petra Hoppmann,† Heribert Schunkert,*§
Karl-Ludwig Laugwitz,†§ Adnan Kastrati,*§ and Dirk Sibbing,‡§
Table S1: Definitions
Hypercholesterolemia
Hypercholesterolemia was diagnosed as documented total
cholesterol of ≥220 mg/dl or prior or ongoing treatment with a
lipid-lowering agent.
Arterial hypertension
Arterial hypertension was diagnosed if the patient was receiving
active treatment with anti-hypertensive drugs or if the systolic
blood pressure was ≥140 mmHg or the diastolic blood pressure
≥90 mmHg on at least two separate occasions.
Diabetes mellitus
The diagnosis of Type 2 diabetes mellitus was based on the
following criteria: history of diabetes with active treatment with
insulin
or
oral
hypoglycaemic
agents
at
admission;
documentation of an abnormal fasting blood glucose (≥126 mg/dl
or ≥7.0 mmol/l) or glucose tolerance test (≥200 mg/dl or ≥11.1
mmol/l) according to WHO (World Health Organization) criteria
for diabetes [World Health Organization (1999) Definition,
Diagnosis and Classification of Diabetes Mellitus and its
Complications: Report of a WHO Consultation. Part 1. Diagnosis
and Classification of Diabetes Mellitus, World Health
Organization, Geneva]; or a blood glucose ≥200 mg/dl at any
time.
Table S2. Baseline characteristics of the propensity score-matched
cohort of patients
Characteristic
Age – yr
Female sex – no. (%)
ASPI >203
(5th quintile)
(n=1414)
68.6 ± 11.3
ASPI≤203
(1st-4th quintile)
(n=1414)
68.9 ± 10.9
P value
0.4
283 (20)
289 (20.4)
0.78
Body Mass Index – kg/m2
27.3 ± 4.4
27.4 ± 4.3
0.53
Diabetes mellitus – no. (%)
380 (26.9)
372 (26.3)
0.73
Arterial hypertension – no. (%)
818 (57.9)
838 (59.3)
0.45
Systolic blood pressure (mmHg)
144.8 ± 25.8
145.7 ± 25.7
0.35
Active smoker – no. (%)
220 (15.6)
217 (15.3)
0.88
Hypercholesterolemia - no. (%)
1000 (70.7)
992 (70.2)
0.77
LDL- cholesterol (mg/dl)
105.7 ± 39.2
106.3 ± 41.3
0.71
HDL-cholesterol (mg/dl)
49.4 ± 15.9
49.9 ± 15.9
0.41
Troponin T (ng/ml)
0.17 ± 0.65
0.15 ± 0.70
0.36
Creatinine (mg/dl)
1.1 ± 0.4
1.1 ± 0.6
0.4
ADP (AU x min)
371.2 ± 277.3
375.8 ± 304.9
0.67
Aspirin at admission - no. (%)
1290 (91.2)
1300 (91.9)
0.49
ADP receptor-blocker at admission - no. (%)
943 (66.7)
941 (66.5)
0.94
ADP receptor-blocker at discharge - no. (%)
None
0.99
6 (0.4)
7 (0.5)
1340 (94.8)
1338 (94.6)
Prasugrel
61 (4.3)
61 (4.3)
Ticagrelor
6 (0.4)
7 (0.5)
Ticlopidin
1 (0.07)
1 (0.07)
Previous MI – no. (%)
357 (25.3)
366 (25.9)
0.69
Multivessel coronary disease - no. (%)
1156 (81.8)
1134 (80.2)
0.29
ACS at presentation – no. (%)
568 (40.2)
557 (39.4)
0.67
Clopidogrel
Legend to Table 1: The table shows the baseline characteristics of the propensity scorematched patients of the study population. Data presented are means  SD or numbers of patients
(percentages). ACS, acute coronary syndrome; ADP, adenosine diphosphate; HDL, highdensity lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; NSTEMI, nonST-segment elevation myocardial infarction; SD, standard deviation; STEMI, ST-segment
elevation myocardial infarction.
Table S3. Clinical outcome of propensity score–matched cohort of
patients
Events, n (%)
ASPI >203
ASPI≤203
(5th quintile)
(1st-4th quintile)
(n=1414)
(n=1414)
Risk approximation p-value
Primary endpoint
Death or ST definite or
ST probable (1 year)
88 (6.2)
63 (4.5)
95 (6.7)
67 (4.7)
HR 1.44 [95% CI
1.04-1.99]
0.027
in-hospital bleeding
TIMI major and minor
OR 1.45 [95% CI
0.023
1.05-1.99]
Legend to Table S2: The table shows the primary clinical outcome data in the HAPR (ASPI
>203) and non-HAPR (ASPI≤203) cohort at one year and in-hospital bleeding results of the
propensity score-matched cohort of patients. Data presented are numbers of patients
(percentages). CI, confidence interval; HR, hazard ratio; ST, stent thrombosis; TIMI,
Thrombolysis in Myocardial Infarction; OR, odds ratio.
Baseline characteristics with regard to availability of platelet function testing
results:
As outlined in Figure 1 (study flow chart), platelet function testing results were available in
7250 patients during the time period of 02/2007 to 05/2013, of which 7090 patients constitute
the ISAR-ASPI registry. Platelet function testing results with regard to on-aspirin treatment
platelet reactivity were not available in 2450 patients during the same time period.
Patients without testing results available (n=2450) vs. registry patients (n=7090) were older,
more frequently women, active smokers and more often had a history or prior MI. Patients
without testing results available less frequently had hypercholesterolemia, arterial hypertension
and an ACS at presentation (P<0.05 for the above mentioned variables).
Other variables including diabetes, multivessel disease, history of bypass surgery and body
mass index did not show significant differences (P≥0.05) between these two groups.